adjuvanted seasonal trivalent influenza vaccine

**Adjuvanted seasonal trivalent influenza vaccine** is an injectable, inactivated seasonal influenza vaccine containing three influenza virus strains (typically H1N1, H3N2, and B/Victoria lineage), formulated with an immune-enhancing adjuvant (such as MF59, a squalene-based oil-in-water emulsion)[3][4][6]. The adjuvant is designed to increase the magnitude and breadth of the immune response, especially in populations with reduced immune function, such as older adults[3]. The vaccine works by inducing antibody production against the hemagglutinin protein of the selected strains, preventing seasonal influenza. It is primarily indicated for prevention of influenza in adults 65 years and older, but is also recommended by regulatory bodies for those eligible according to age and risk categories[2][4][6]. Developed and marketed primarily as Fluad, this vaccine has a well-documented safety and efficacy profile established through FDA pathway approval[3].

Brand names

Fluad

Other names

aIIV3aIIV-3aIIV 3Fluad Adjuvant Trivalent